Insider Trading (Form 4)
NASDAQ
Naum Muchnik, VP of R&D and Engineering at IceCure Medical Ltd., has filed an exit Form 4, reporting his departure and cessation of Section 16 reporting obligations.
NASDAQ
Ronen Tsimerman has filed an exit Form 4, indicating he is no longer the Chief Financial Officer of IceCure Medical Ltd. as of May 17, 2026.
Schedule 13D - Activist Investments
NASDAQ
A significant shareholder's director, Mr. Li Haixiang, has resigned from the board of IceCure Medical Ltd., while the reporting persons maintain a 45.8% beneficial ownership stake.
NASDAQ
SCHEDULE 13D: Major Shareholder Li Haixiang and Epoch Partner Investments Disclose 45.7% Stake in IceCure Medical Ltd.
Li Haixiang and Epoch Partner Investments Limited have disclosed a significant beneficial ownership of 45.7% in IceCure Medical Ltd., holding 25,846,597 ordinary shares for investment purposes.
Schedule 13G - Passive Investments
NASDAQ
Armistice Capital, LLC and Steven Boyd have jointly reported beneficial ownership of 300,332 ordinary shares, representing 9.99% of IceCure Medical Ltd., as of June 30, 2026.